ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2510

Patient and Provider Factors Associated with Compliance with Rheumatoid Arthritis Treatment Recommendations

Leslie R. Harrold1, George W. Reed2, Katherine C. Saunders3, Ying Shan1, Tanya Spruill4 and Jeffrey D. Greenberg5, 1Dept of Medicine, UMass Medical School, Worcester, MA, 2University of Massachusetts Medical School, Worcester, MA, 3Corrona, LLC., Southborough, MA, 4Center for Healthful Behavior Change, Department of Population Health, NYU School of Medicine, New York, NY, 5New York Hospital for Joint Disease, New York, NY

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Quality of care and rheumatoid arthritis, treatment

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: ACR/ARHP Combined Epidemiology Abstract Session

Session Type: Combined Abstract Sessions

Background/Purpose:  Only approximately 50% of rheumatoid arthritis (RA) patient with active disease receive care consistent with the American College of Rheumatology (ACR) recommendations for the use of biologic and nonbiologic disease modifying anti-rheumatic drugs (DMARDs).  Therefore we examined patient and provider factors associated with receipt of the recommended care using data from a multi-center observational registry within the United States (the Consortium of Rheumatology Researchers of North America: CORRONA). 

 

Methods:   We identified biologic naïve RA patients cared for within the CORRONA network between 12/08 and 12/11.  Initiation or dose escalation of biologic and nonbiologic DMARDs in response to active disease (using the Clinical Disease Activity Index) was assessed in comparison to the ACR recommendations.  The population was divided into two mutually exclusive cohorts: 1) methotrexate (MTX) only users; and 2) multiple non-biologic DMARD users.  We compared the characteristics of patients (age, gender, race/ethnicity, working status, insurance and RA disease characteristics) who received care consistent with the ACR recommendations and their treating providers (gender, years since medical school graduation, academic vs. private practice and region of the country [Northeast, South, Midwest and West]) to those who did not in the two cohorts with active disease using logistic regression adjusting for clustering of physicians and patients.

Results:  There were 5,196 patients who met inclusion criteria cared for by 191 providers at 86 practice sites.  Of the 991 MTX only users with active disease (moderate disease activity with a poor prognosis or high disease activity), 44% received care consistent with the treatment recommendations.  In adjusted analyses, patient characteristics including age 65 and older (OR 0.70; 95% CI 0.54-0.91), female gender (OR 1.47, 95% CI 1.10-1.98) and prednisone dose (OR 1.37, 95%CI 1.05-1.79) were associated with care practices while physician characteristics were not.  Among the 1209 multiple nonbiologic DMARD users with moderate or high disease activity, 48% received care consistent with the recommendations.  Patient age 65 and older (OR 0.73, 95% 0.57-0.94), residence in the South (OR 0.69, 95% CI 0.50-0.94) or Midwest (OR 0.73, 95% CI 0.54-0.99) and care by a private practice rheumatologist (OR 0.56, 95% CI 0.37-0.83) were associated with a reduced likelihood of receiving care consistent with the recommendations.  

 

Conclusion:   Compliance with the ACR treatment recommendations is influenced by both patient and provider characteristics.  Identification of these characteristics will help us identify which patients and providers to target for interventions to improve care. 

 

 


Disclosure:

L. R. Harrold,

NIH-K23AR053856,

2,

Corrona,

5;

G. W. Reed,

Corrona,

2,

University of Massachusetts Medical School,

3,

Corrona,

5,

Harvard Medical School,

;

K. C. Saunders,

Corrona,

3;

Y. Shan,
None;

T. Spruill,
None;

J. D. Greenberg,

Corrona,Inc.,

1,

Astra Zeneca, Corrona, inc. Novartis, Pfizer,

5.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/patient-and-provider-factors-associated-with-compliance-with-rheumatoid-arthritis-treatment-recommendations/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology